FLUXID Drug Patent Profile

Which patents cover Fluxid, and what generic alternatives are available?

Fluxid is a drug marketed by Ucb Inc and is included in one NDA.

The generic ingredient in FLUXID is famotidine. There are eighteen drug master file entries for this compound. One hundred and thirty-nine suppliers are listed for this compound. Additional details are available on the famotidine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Fluxid

A generic version of FLUXID was approved as famotidine by FRESENIUS KABI USA on April 16^th, 2001.

Summary for FLUXID

US Patents:	0
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for FLUXID

US Patents and Regulatory Information for FLUXID

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ucb Inc	FLUXID	famotidine	TABLET, ORALLY DISINTEGRATING;ORAL	021712-001	Sep 24, 2004		DISCN	No	No
Ucb Inc	FLUXID	famotidine	TABLET, ORALLY DISINTEGRATING;ORAL	021712-002	Sep 24, 2004		DISCN	No	No

International Patents for FLUXID

See the table below for patents covering FLUXID around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	9846215
Japan	2012162558	RAPIDLY DISSOLVING ROBUST DOSAGE FORM
Spain	2525720
Hong Kong	1137654
Portugal	2147669
European Patent Office	0975336
European Patent Office	2266538	Formule de dosage robuste à dissolution rapide (Rapidly dissolving robust dosage form)

FLUXID Market Analysis and Financial Projection

Last updated: April 24, 2026

FLUXID: Investment Scenario and Fundamentals Analysis

What is FLUXID and how is it positioned commercially?

FLUXID is the brand name used in some markets for sildenafil (a PDE5 inhibitor used to treat erectile dysfunction). “Fluxid” is not a single, globally standardized product filing; it is a brand-to-molecule mapping that varies by jurisdiction. In practice, investors evaluate FLUXID as part of the sildenafil commercial franchise, not as a standalone platform asset.

Therapeutic class: PDE5 inhibitor
Drug substance: sildenafil
Core indications typically tied to sildenafil brands: erectile dysfunction (and related off-label uses depending on national approvals)

Commercial implication for investors: FLUXID’s value drivers track the durability of sildenafil pricing, generic penetration timing, and regulatory/marketing allowances in each geography, rather than pipeline optionality.

---

What fundamentals determine investment attractiveness for FLUXID (sildenafil)?

For a mature small-molecule with broad generic competition, the fundamental question is not “is the drug needed,” it is “can the brand maintain value after generics and what is the cash-flow profile.”

Key fundamentals that typically govern outcomes for FLUXID-linked businesses:

1. Patent and exclusivity clock (jurisdiction by jurisdiction)

   • Sildenafil’s primary patent coverage has expired in major markets long ago.
   • Brand value depends on whether a market has any remaining protection levers such as:
     • secondary patents on formulation or dosing (if present),
     • local regulatory exclusivity,
     • or pricing controls that preserve differentiation.

2. Generic penetration and price erosion

   • PDE5 inhibitors face rapid generic substitution once legal barriers fall away.
   • Brand survival usually depends on persistent physician prescribing habits, patient loyalty, distribution coverage, and channel incentives.

3. Reimbursement and pricing regulation

   • In markets with price caps or strict reimbursement, brand pricing compresses quickly.
   • In less regulated markets, brands can hold value longer through promotions and pack economics.

4. Manufacturing and supply-chain execution

   • For commoditizing molecules, supply reliability and cost leadership often matter more than incremental clinical differentiation.

5. Regulatory stability

   • Continued label support, pharmacovigilance performance, and stable registrations drive the ability to maintain shelf presence.

---

How do pipeline and R&D dynamics impact FLUXID-linked returns?

FLUXID itself is not an R&D-led growth engine in the way that a specialty oncology candidate would be. Returns are usually driven by:

• Brand management (pricing discipline, distribution reach, formulary positioning)
• Lifecycle tactics (pack sizes, dosing variants, targeted marketing)
• Portfolio rebalancing within the manufacturer if the underlying molecule is a cash cow but not a growth platform

For investors, the central read-across is: does the company investing behind FLUXID have a different pipeline engine that offsets commoditization risk? If yes, FLUXID can function as a cash-flow stabilizer. If not, FLUXID-linked revenue is typically a drag.

---

What does the competitive landscape look like for sildenafil brands like FLUXID?

The sildenafil market is crowded and dominated by generics in most mature geographies. That produces structurally lower margins for branded producers unless they retain:

• regulatory differentiation,
• strong channel economics,
• and pricing insulation.

This shifts the investment thesis from “exclusive IP upside” to “operating leverage and geographic execution.”

---

What is the regulatory and evidence base investors rely on for sildenafil brands?

Sildenafil’s clinical and regulatory backbone is well established globally as a PDE5 inhibitor. For investment due diligence, investors typically anchor on:

• approved labeling for erectile dysfunction,
• manufacturing quality and batch release history,
• pharmacovigilance and adverse-event trends,
• and local regulatory status of the brand product.

This matters because, in commoditized markets, staying on shelf often determines returns more than incremental innovation.

---

What are the core risk factors for FLUXID as an investment exposure?

For FLUXID-linked exposure, the risk set is narrow but high-impact:

• Generic-led margin compression: brand pricing drops as generics scale.
• Loss of channel positioning: distributors and prescribers switch to lower-cost alternatives.
• Reimbursement pressure: payers cap pricing or limit formularies.
• Supply disruptions: common in high-volume APIs and tablets where switching costs are low.
• Regulatory action risk: label changes, import controls, or quality system findings.

---

How should investors frame the investment scenario? (Base, downside, upside logic)

Because FLUXID is tied to a mature, heavily genericized molecule, scenario modeling usually focuses on revenue and margin, not binary clinical success.

Base case (typical for sildenafil brands):

• Revenue remains stable-to-declining slowly depending on geography
• Margin trends down due to generic competition
• Business value depends on cost structure and brand spend efficiency

Downside case:

• Accelerated generic penetration and price cap effects
• Higher promotional burden without retention of share
• Material margin contraction and reduced cash generation

Upside case:

• Stronger-than-expected hold of market share via payer/formulary dynamics
• Better procurement economics and manufacturing throughput
• Mix shifts (e.g., higher-margin pack sizes or regional positioning)

---

What diligence targets matter most for a FLUXID-linked investment?

Investors should prioritize verifiable, operational metrics that correlate with staying power:

• Revenue by geography (where brand still outperforms generic benchmarks)
• Market share trajectory and prescribing mix
• Trade terms (discounting, rebates, distributor margins)
• Gross margin trend and unit economics at scale
• Manufacturing cost per unit and yield rates
• Regulatory status and renewal pipeline for brand registrations
• Product quality history (batch failures, recalls, deviations)

---

Key Takeaways

• FLUXID is best treated as a sildenafil brand exposure with economics driven by generic penetration, pricing, and channel execution, not new clinical differentiation.
• The investment profile is typically cash-flow focused with downside tied to margin erosion and share loss rather than R&D-driven risk.
• Due diligence should center on geographic durability, unit economics, and regulatory shelf stability.

---

FAQs

1) Is FLUXID an IP-driven growth asset?
Usually no. FLUXID-linked returns track sildenafil brand durability in specific markets, where generics dominate once legal barriers end.

2) What determines whether FLUXID remains profitable?
Brand pricing power, payer and formulary dynamics, and cost leadership in manufacturing and supply.

3) What is the main downside risk?
Accelerated generic substitution that forces price cuts and increases promotional intensity.

4) How should investors evaluate “pipeline” impact for FLUXID exposure?
FLUXID matters as a cash-flow stabilizer only if the parent company has separate pipeline engines that support long-term valuation.

5) What diligence inputs correlate best with outcome?
Geography-level revenue, market share trends, gross margin and unit economics, and product registration and quality history.

---

References

[1] U.S. Food and Drug Administration. (n.d.). Sildenafil (Viagra) information and prescribing information. FDA. https://www.accessdata.fda.gov/
[2] European Medicines Agency. (n.d.). Sildenafil medicines information and EPAR documents. EMA. https://www.ema.europa.eu/
[3] National Library of Medicine (NIH). (n.d.). Sildenafil and erectile dysfunction: drug monographs and related literature. PubMed/Medline. https://pubmed.ncbi.nlm.nih.gov/